We are lowering our adjusted EBITDA, adjusted EPS and capital expenditures outlook for fiscal 2023. We've updated our guidance to revenue of $6,150,000,000 to $6,275,000,000 which is unchanged Adjusted EBITDA of $460,000,000 to $480,000,000 Interest expense of $145,000,000 to 155,000,000 which is unchanged. Adjusted EPS of $0.24 to $0.30 on $269,000,000 weighted average fully diluted shares, $215,000,000 to $225,000,000 of capital expenditures, and we continue to expect to add a total of 50 to 55 owned vet hospitals in 2023 in approximately 10 Continued pressure on gross margins, given continued mix pressures away from discretionary, along with strategic pricing actions we are undertaking to accelerate growth and retention, which we have seen positive returns on in prior iterations. When the discretionary environment stabilizes, coupled with the outcome of our cost actions and productivity, We expect our gross margins will stabilize. Importantly, we've seen continued improvement in services and ecom gross margins.